DK2300452T3 - 5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister - Google Patents

5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister

Info

Publication number: DK2300452T3
Authority: DK; Denmark
Prior art keywords: methylpropanoylmethylamino; prolinamide; pyridinyl; methylphenyl; trifluoromethyl
Prior art date: 2008-05-14

Application number

DK09745725.3T

Other languages

English (en)

Inventor

Giuseppe Alvaro

Agostino Marasco

Original Assignee

Nerre Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-14

Filing date

2009-05-12

Publication date

2014-02-17

2009-05-12 Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd

2014-02-17 Application granted granted Critical

2014-02-17 Publication of DK2300452T3 publication Critical patent/DK2300452T3/da

Links

-1 bis (trifluoromethyl) phenyl Chemical group 0.000 title 2
102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Gynecology & Obstetrics (AREA)

DK09745725.3T 2008-05-14 2009-05-12 5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister DK2300452T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0808747.0A GB0808747D0 (en)	2008-05-14	2008-05-14	Novel compounds
PCT/EP2009/055700 WO2009138393A1 (en)	2008-05-14	2009-05-12	5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists

Publications (1)

Publication Number	Publication Date
DK2300452T3 true DK2300452T3 (da)	2014-02-17

Family

ID=39571329

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09745725.3T DK2300452T3 (da)	2008-05-14	2009-05-12	5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister

Country Status (22)

Country	Link
US (4)	US8344005B2 (da)
EP (1)	EP2300452B1 (da)
JP (1)	JP5465716B2 (da)
KR (1)	KR101567116B1 (da)
CN (1)	CN102105458B (da)
AR (1)	AR071721A1 (da)
AU (1)	AU2009248102B8 (da)
BR (1)	BRPI0911990B1 (da)
CA (1)	CA2724219C (da)
CL (1)	CL2009001146A1 (da)
DK (1)	DK2300452T3 (da)
EA (1)	EA019037B1 (da)
ES (1)	ES2446866T3 (da)
GB (1)	GB0808747D0 (da)
IL (1)	IL209197A (da)
MX (1)	MX2010012421A (da)
PE (1)	PE20091847A1 (da)
PL (1)	PL2300452T3 (da)
TW (1)	TWI444376B (da)
UY (1)	UY31824A (da)
WO (1)	WO2009138393A1 (da)
ZA (1)	ZA201007904B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8426450B1 (en) *	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
BR112016009811A2 (pt)	2013-11-08	2017-12-05	Kissei Pharmaceutical	derivado de carboximetil piperidina
TWI649307B (zh)	2014-05-07	2019-02-01	日商橘生藥品工業股份有限公司	Cyclohexylpyridine derivative
WO2016021562A1 (ja) *	2014-08-06	2016-02-11	キッセイ薬品工業株式会社	シアノチオフェン誘導体
WO2018197638A1 (en)	2017-04-27	2018-11-01	Nerre Therapeutics Limited	Novel use of (5r)-5-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-2-methyl-d-prolinamide
WO2021154631A1 (en) *	2020-01-30	2021-08-05	Javed Mohammad	Combination drug therapies for cns disorders
CA3177477A1 (en) *	2020-06-02	2021-12-09	Nerre Therapeutics Limited	Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
US11548879B1 (en) *	2020-07-01	2023-01-10	Ecstasy LLC	Polycyclics as sigma receptor modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1394150T3 (da)	1999-02-24	2011-03-21	Hoffmann La Roche	4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
WO2000050398A2 (en)	1999-02-24	2000-08-31	F. Hoffmann-La Roche Ag	Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
US6303790B1 (en)	1999-11-29	2001-10-16	Hoffman-La Roche Inc.	Process for the preparation of pyridine derivatives
CN1178917C (zh)	2000-07-14	2004-12-08	弗·哈夫曼-拉罗切有限公司	作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
TWI287003B (en)	2000-07-24	2007-09-21	Hoffmann La Roche	4-phenyl-pyridine derivatives
TWI259180B (en)	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
MXPA03009720A (es)	2001-04-23	2004-01-29	Hoffmann La Roche	USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en)	2001-07-31	2005-02-01	Hoffmann-La Roche Inc.	Aromatic and heteroaromatic substituted amides
HRP20070471T3 (hr) *	2003-07-03	2007-11-30	F. Hoffmann - La Roche Ag	Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
MX2007000198A (es)	2004-07-06	2007-03-15	Hoffmann La Roche	Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
US20060030600A1 (en) *	2004-08-06	2006-02-09	Patrick Schnider	Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US7683056B2 (en) *	2005-09-09	2010-03-23	Glaxosmithkline Llc	Pyridine derivatives and their use in the treatment of psychotic disorders
ATE472529T1 (de) *	2005-10-10	2010-07-15	Glaxo Group Ltd	Prolinamidderivate als natriumkanalmodulatoren

2008
- 2008-05-14 GB GBGB0808747.0A patent/GB0808747D0/en not_active Ceased
2009
- 2009-05-12 CL CL2009001146A patent/CL2009001146A1/es unknown
- 2009-05-12 CA CA2724219A patent/CA2724219C/en active Active
- 2009-05-12 BR BRPI0911990-6A patent/BRPI0911990B1/pt not_active IP Right Cessation
- 2009-05-12 EA EA201071299A patent/EA019037B1/ru not_active IP Right Cessation
- 2009-05-12 AU AU2009248102A patent/AU2009248102B8/en not_active Ceased
- 2009-05-12 PL PL09745725T patent/PL2300452T3/pl unknown
- 2009-05-12 US US12/991,515 patent/US8344005B2/en not_active Expired - Fee Related
- 2009-05-12 MX MX2010012421A patent/MX2010012421A/es active IP Right Grant
- 2009-05-12 US US12/464,171 patent/US20090286836A1/en not_active Abandoned
- 2009-05-12 DK DK09745725.3T patent/DK2300452T3/da active
- 2009-05-12 EP EP09745725.3A patent/EP2300452B1/en active Active
- 2009-05-12 JP JP2011508893A patent/JP5465716B2/ja not_active Expired - Fee Related
- 2009-05-12 CN CN2009801275140A patent/CN102105458B/zh not_active Expired - Fee Related
- 2009-05-12 AR ARP090101713A patent/AR071721A1/es not_active Application Discontinuation
- 2009-05-12 TW TW098115612A patent/TWI444376B/zh not_active IP Right Cessation
- 2009-05-12 ES ES09745725.3T patent/ES2446866T3/es active Active
- 2009-05-12 WO PCT/EP2009/055700 patent/WO2009138393A1/en not_active Ceased
- 2009-05-12 UY UY0001031824A patent/UY31824A/es not_active Application Discontinuation
- 2009-05-12 KR KR1020107027927A patent/KR101567116B1/ko not_active Expired - Fee Related
- 2009-05-12 PE PE2009000650A patent/PE20091847A1/es not_active Application Discontinuation
2010
- 2010-11-04 ZA ZA2010/07904A patent/ZA201007904B/en unknown
- 2010-11-08 IL IL209197A patent/IL209197A/en active IP Right Grant
2012
- 2012-11-20 US US13/681,925 patent/US8822504B2/en active Active
2014
- 2014-05-16 US US14/280,280 patent/US9006271B2/en active Active

Also Published As

Publication number	Publication date
PL2300452T3 (pl)	2014-04-30
TW201006813A (en)	2010-02-16
US9006271B2 (en)	2015-04-14
CN102105458A (zh)	2011-06-22
US20130143931A1 (en)	2013-06-06
US20110060015A1 (en)	2011-03-10
KR101567116B1 (ko)	2015-11-06
CN102105458B (zh)	2013-06-12
JP5465716B2 (ja)	2014-04-09
ZA201007904B (en)	2011-11-30
MX2010012421A (es)	2011-03-25
CL2009001146A1 (es)	2010-09-24
ES2446866T3 (es)	2014-03-10
AR071721A1 (es)	2010-07-07
UY31824A (es)	2009-11-10
EA201071299A1 (ru)	2011-06-30
CA2724219A1 (en)	2009-11-19
CA2724219C (en)	2016-04-05
WO2009138393A1 (en)	2009-11-19
AU2009248102A1 (en)	2009-11-19
PE20091847A1 (es)	2010-01-09
BRPI0911990B1 (pt)	2021-07-13
EA019037B1 (ru)	2013-12-30
KR20110017384A (ko)	2011-02-21
US8344005B2 (en)	2013-01-01
EP2300452A1 (en)	2011-03-30
IL209197A (en)	2014-09-30
IL209197A0 (en)	2011-01-31
US20140249188A1 (en)	2014-09-04
TWI444376B (zh)	2014-07-11
AU2009248102B8 (en)	2012-07-26
US20090286836A1 (en)	2009-11-19
GB0808747D0 (en)	2008-06-18
EP2300452B1 (en)	2013-11-20
BRPI0911990A2 (pt)	2020-08-18
JP2011520834A (ja)	2011-07-21
AU2009248102B2 (en)	2012-06-28
US8822504B2 (en)	2014-09-02

Publication	Publication Date	Title
BRPI0914772A2 (pt)	2015-10-20	compostos heterocíclicos 1,2-dissubstituídos
BRPI0923786A2 (pt)	2016-07-26	compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
BRPI0817537A2 (pt)	2015-03-31	4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
DK2069374T4 (da)	2021-10-18	Krystallinske solvater af (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl)phenyl)-d-glucitolderivater med alkoholer som sglt2-inhibitorer til behandling af diabetes
EP2349270A4 (en)	2012-04-25	2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
EP2244576A4 (en)	2011-06-08	3,5-substituted-1,3-oxazolidine-2-one derivatives
DK2089382T3 (da)	2013-02-04	Substituerede diazepan-forbindelser som orexin-receptor-antagonister
RU2465270C3 (ru)	2017-03-28	Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
EP2349262A4 (en)	2012-08-29	2,5-DISUBSTITUTED PHENYL CARBOXYLIC ACID AMOID-OREXINE RECEPTOR ANTAGONISTS
DK2010498T3 (da)	2011-02-14	Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister
DK2206710T3 (da)	2012-08-27	Indolderivater som s1p1-receptor agonister
DK2200985T3 (da)	2011-10-24	1,3-Disubstituerede 4-(aryl--X-phenyl)-1H-pyridin-2-oner
ATE509928T1 (de)	2011-06-15	8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
PL2365754T3 (pl)	2017-03-31	Kompozycje środków chwastobójczych zawierające związki benzoilopirazolowe
BRPI0815440A2 (pt)	2017-05-30	5-substituidos 2- (alcoximetil) furanos
PL2123158T3 (pl)	2016-03-31	Kompozycja chwastobójcza
IL209197A0 (en)	2011-01-31	5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
EP2091329A4 (en)	2011-02-23	Indazole CONNECTIONS
EP2129224A4 (en)	2011-01-05	5,6-dihydro-1H-pyridin-2-one compounds
DK2089367T3 (da)	2012-02-06	Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
EP2088861A4 (en)	2010-07-07	Benzimidazole compounds
DK3252069T3 (da)	2019-06-24	(11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-oner til behandling af sygdomme
BRPI0811446A2 (pt)	2014-10-29	" 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil pirazinas e piridinas e 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas de receptor 5-ht7"
BRPI0913806A2 (pt)	2015-10-20	"composição"
DK2125714T3 (da)	2011-07-25	Hydrochloridsalt af 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamid